---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-26-000008"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:14:39.206749+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics reports Q4 2025 net product revenue $1.6M from VIZZ launch; net loss $35.9M

## Summary
- Q4 net product revenue $1.6M from VIZZ aceclidine eye drop for presbyopia; over 20,000 filled prescriptions.
- Net loss $35.9M ($1.16 per share) for Q4 2025 vs $12.7M in Q4 2024; cash $292.3M at year-end.
- Over 6,500 unique prescribers in Q4, on pace for 10,000+ through Q1 2026; >55% wrote multiple times.
- Sales force expanding from 88 to 117 territories in Q2 2026; MAA submitted to EMA in March 2026.
- Launched 'Make it VIZZable' DTC campaign with Sarah Jessica Parker; website traffic up 10x.

## SEC filing metadata
- accession: 0001815776-26-000008
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/0001815776-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/lenz-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-26-000008
- JSON: https://secwatch.observer/filing/0001815776-26-000008.json
- Plain text: https://secwatch.observer/filing/0001815776-26-000008.txt

## Key facts
- Earnings Releases
  LENZ Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $1.6 million.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Revenue: $1.6 million
  - Result: reported results
  source text: and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/0001815776-26-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.